UBS analyst Joshua Spector raised the firm’s price target on Corteva (CTVA) to $76 from $74 and keeps a Buy rating on the shares. Corteva posted a “solid” first half of the year and there is no change to 2025 guidance, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva’s Strong Q1 Performance and Strategic Initiatives Justify Buy Rating
- Corteva’s Growth Potential and Operational Efficiency Justify Buy Rating Despite Conservative Guidance
- Corteva reports Q1 non-GAAP EPS $1.13, consensus 88c
- Corteva still sees 2025 operating EPS $2.70-$2.95, consensus $2.95
- Corteva Stockholders Approve Key Proposals at Annual Meeting